A van der Gaast
Overview
Explore the profile of A van der Gaast including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Konings I, de Jonge M, Burger H, van der Gaast A, van Beijsterveldt L, Winkler H, et al.
Br J Cancer
. 2010 Sep;
103(7):987-92.
PMID: 20823884
Background: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor...
12.
Konings I, van der Gaast A, van der Wijk L, de Jongh F, Eskens F, Sleijfer S
Eur J Cancer
. 2010 Aug;
46(18):3200-4.
PMID: 20727735
Purpose: Statins have for long been considered to play a potential role in anticancer treatment based upon their ability to inhibit the mevalonate synthesis pathway. This randomised phase II trial...
13.
Boonstra J, Koppert L, Wijnhoven B, Tilanus H, van Dekken H, Tran T, et al.
J Surg Oncol
. 2009 Aug;
100(5):407-13.
PMID: 19653239
Background: Patients with carcinoma of the distal esophagus and metastatic celiac lymph nodes (M1a) have a poor prognosis and are often denied surgery. In this study, we evaluated our treatment...
14.
van Meerten E, van der Gaast A, Tilanus H, Poley J, Muller K, van Dekken H
J Surg Oncol
. 2009 Apr;
100(1):32-7.
PMID: 19402081
Multimodality treatment is increasingly used in the treatment for esophageal cancer. We determined the tumor regression grade after preoperative chemoradiation and correlated the effect of specific pathologic and clinical findings...
15.
Verschuur E, Steyerberg E, Tilanus H, Polinder S, Essink-Bot M, Tran K, et al.
Br J Cancer
. 2008 Dec;
100(1):70-6.
PMID: 19066612
Between January 2004 and February 2006, 109 patients after intentionally curative surgery for oesophageal or gastric cardia cancer were randomised to standard follow-up of surgeons at the outpatient clinic (standard...
16.
van Heijl M, van Lanschot J, Koppert L, van Berge Henegouwen M, Muller K, Steyerberg E, et al.
BMC Surg
. 2008 Nov;
8:21.
PMID: 19036143
Background: A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases (cT1-3 N0-1 M0). A high...
17.
van Meerten E, Eskens F, van Gameren E, Doorn L, van der Gaast A
Br J Cancer
. 2007 Apr;
96(9):1348-52.
PMID: 17437008
This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fifty-one eligible patients received oxaliplatin 130 mg m(-2) intravenously on day...
18.
van Vliet E, Eijkemans M, Steyerberg E, Kuipers E, Tilanus H, van der Gaast A, et al.
Br J Cancer
. 2006 Oct;
95(9):1180-5.
PMID: 17031405
In the United States (USA), a correlation has been demonstrated between socio-economic status (SES) of patients on the one hand, and tumour histology, stage of the disease and treatment modality...
19.
Siersema P, Rosenbrand C, Bergman J, van der Gaast A, Goedhart C, Richel D, et al.
Ned Tijdschr Geneeskd
. 2006 Sep;
150(34):1877-82.
PMID: 16970009
An evidence-based guideline for the diagnosis and treatment of oesophageal carcinoma was developed on the initiative of the Netherlands Society of Gastroenterohepatology in cooperation with the Dutch Institute for Healthcare...
20.
Verschuur E, Steyerberg E, Kuipers E, Essink-Bot M, Tran K, van der Gaast A, et al.
Eur J Cancer Care (Engl)
. 2006 Sep;
15(4):324-32.
PMID: 16968313
We investigated which problems patients experience after resection for oesophageal cancer and what care they expect, in order to devise a better-tailored follow-up policy. Thirty patients, all within 1 year...